Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 11/2018

01-11-2018 | Original paper

Acceptability of two- versus three-dose human papillomavirus vaccination schedule among providers and mothers of adolescent girls: a mixed-methods study in five countries

Authors: Jessica Yasmine Islam, Alexis M. Hoyt, Silvina Ramos, Karen Morgan, Chan Joo Kim, Sylvia de Sanjose, Nicole Butera, Virginia Senkomago, Karin L. Richter, Mary Anne McDonald, Nadja A. Vielot, Jennifer S. Smith

Published in: Cancer Causes & Control | Issue 11/2018

Login to get access

Abstract

Purpose

The World Health Organization revised its human papillomavirus (HPV) vaccination recommendations to include a two (2-) dose schedule for girls aged ≤ 15 years. We investigated acceptability of 2- versus 3-dose schedule among adolescent vaccination providers and mothers of adolescent girls in five countries.

Methods

Adolescent vaccination providers (N = 151) and mothers of adolescent girls aged 9–14 years (N = 118) were recruited from Argentina, Malaysia, South Africa, South Korea, and Spain. We assessed providers’ preference for a 2- versus 3-dose HPV vaccination schedule via quantitative surveys. Mothers’ attitudes towards a 2-dose schedule were assessed through focus group discussions.

Results

Most adolescent providers preferred a 2- over a 3-dose HPV vaccination schedule (overall: 74%), with preference ranging from 45.2% (South Africa) to 90.0% (South Korea). Lower cost, fewer clinic visits, and higher series completion were commonly cited reasons for 2-dose preference among providers and mothers. Safety and efficacy concerns were commonly cited barriers to accepting a 2-dose HPV vaccination schedule among providers and mothers. Mothers generally accepted the reduced schedule, however requested further information from a trusted source.

Conclusions

Adolescent vaccination providers and mothers preferred the 2-dose over 3-dose HPV vaccination schedule. Acceptability of a 2-dose HPV vaccination could be improved with additional information to providers and mothers on HPV vaccination safety and efficacy.
Appendix
Available only for authorised users
Literature
1.
World Health Organization (2014) Human papillomavirus vaccines: WHO position paper. World Health Organization, Geneva
2.
World Health Organization (2017) Human papillomavirus vaccines: WHO position paper, May 2017. World Health Organization, Geneva
3.
Clendinen C, Zhang Y, Warburton R, Light D (2016) Manufacturing costs of HPV vaccines for developing countries. Vaccine 34(48):5984–5989CrossRef
4.
Remes P, Selestine V, Changalucha J, Ross D, Wight D, de Saniose S, Hayes R, Watson-Jones D (2012) A qualitative study of HPV vaccine acceptability among health workers, teachers, parents, female pupils, and religious leaders in northwest Tanzania. Vaccine 30(36):5363–5367CrossRef
5.
LaMontagne D, Barge S, Le N, Mugisha E, Penny M, Gandhi S, Janmohamed A, Kumakech E, Mosqueira N, Nguyen N, Paul P, Tang Y, Minh T, Uttekar B, Jumaan A (2011) Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ 89(11):821–830BCrossRef
6.
Brewer N, Fazekas K (2007) Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 45(2–3):107–114CrossRef
7.
Wigle JCE, Watson-Jones D (2013) Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMIC): health system experiences and prospects. Vaccine 31(37):3811–3817CrossRef
8.
Lazcano-Ponce E, Stanley M, Muñoz N, Torres L, Cruz-Valdez A, Salmerón J, Rojas R, Herrero R, Hernández-Ávila M (2014) Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 32(6):725–732CrossRef
9.
Dobson S, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele D, Kollmann T, Halperin S, Langley J, Bettinger J, Singer J, Money D, Miller D, Naus M, Marra F, Young E (2013) Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 309(17):1793–1802CrossRef
10.
Romanowski B, Schwarz T, Ferguson L, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, Schuind A, Descamps D (2011) Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccine 7(12):1374–1386CrossRef
11.
Romanowski B, Schwarz T, Ferguson M, Klaus P, Dionne M, Schulze K, Ramjattan B, Hillemanss P, Behre U, Suryakiran P, Thomas F, Struyf F (2014) Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination. Hum Vaccines Immunother 10(5):1155–1165CrossRef
12.
Romanowski B, Schwarz T, Ferguson L, Peters K, Dionne M, Behre U, Hillemanns P, Suryakiran P, Thomas F, Struyf F (2016) Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study. Vaccine 12(1):20–29CrossRef
13.
14.
Francis S, Katz M (2013) The HPV vaccine: a comparison of focus groups conducted in South Africa and Ohio Appalachia. Matern Child Health J 17(7):1222–1229CrossRef
15.
Hertweck S, LaJoie A, Pinto M, Flamini L, Lynch T, Logsdon M (2013) Health care decision making by mothers for their adolescent daughters regarding the quadrivalent HPV vaccine. J Pediatr Adolesc Gynecol 26(2):96–101CrossRef
16.
Katz I, Nkala B, Dietrich J, Wallace M, Bekker L, Pollenz K, Bogart L, Wright A, Tsai A, Bangsberg D, Gray G (2013) A qualitative analysis of factors influencing HPV vaccine uptake in Soweto, South Africa among adolescents and their caregivers. PLoS ONE 8(8):e72094CrossRef
17.
Rambout L, Tashkandi M, Hopkins L, Tricco A (2014) Self-reported barriers and facilitators to preventive human papillomavirus vaccination among adolescent girls and young women: a systematic review. Prev Med 58:22–32CrossRef
18.
Oh J, Lim M, Yun E, Lee E, Shin H (2010) Awareness of and attitude towards human papillomavirus infection and vaccination for cervical cancer prevention among adult males and females in Korea: a nationwide interview survey. Vaccine 28(7):1854–1860CrossRef
19.
Navarro-Illana P, Caballero P, Tuells J, Puig-Barbera J, Diez-Domingo J (2015) Acceptability of human papillomavirus vaccine in mothers from Valencia (Spain). An Pediatr 83(5):318–327CrossRef
20.
Watson-Jones D, Mugo N, Lee S, Mathai M, Vusha S, Ndirangu G, Ross D (2015) Access and attitudes of HPV vaccination amongst hard-to-reach populations in Jenya. PLoS ONE 10(6):e0123701CrossRef
21.
Crann S, Barata P, Mitchell R, Mawhinney LT, Chirenje P, Stewart M D (2016) Healthcare providers’ perspectives on the acceptability and uptake of HPV vaccines in Zimbabwe. J Psychosom Obstet Gynecol 37(4):147–155CrossRef
22.
Hopkins T, Wood N (2013) Female human papillomavirus (HPV) vaccination: global uptake and the impact of attitudes. Vaccine 31(13):1673–1679CrossRef
23.
Asiedu G, Breitkopf C, Kremers W, Ngo Q, Nguyen N, Barenberg B, Tran V, Dinh T (2015) Vietnamese health care providers’ preferences regarding recommendation of HPV vaccines. Asian Pac J Cancer Prev 16(12):4895–4900CrossRef
24.
25.
McLellan E, MacQueen KM, Neidig JL (2003) Beyond the qualitative interview: data preparation and transcription. Field Methods 15(1):63–84CrossRef
26.
Vaismoradi M, Turunen H, Bondas T (2013) Content analysis and thematic analysis: implications for conducting a qualitative descriptive study. Nurs Health Sci 15(4):398–405CrossRef
27.
MacQueen KM, McLellan-Lemal E, Bartholow K, Milstein B (2008) Team-based codebook development: structure, process and agreement. In: Handbook for team-based qualitative research. Altamina Press, Lanham, pp 119–135
28.
Bernard HR, Ryan GW (2010) Analyzing qualitative data: systematic approaches. Sage, Thousand Oaks
29.
Guest G, MacQueen KM, Namey EE (2012) applied thematic analysis. Sage, Thousand OaksCrossRef
30.
Saldana J (2013) The coding manual for qualitative researchers, 3rd edn. Sage, Thousand Oaks
31.
Jit M, Brisson M, Laprise J, Hong Choi Y (2015) Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ 350
32.
Laprise J, Markowitz L, Chesson H, Drolet M, Brisson M (2016) Comparison of 2-dose and 3-dose 9-valent human papillomavirus vaccine schedules in the United States: a cost-effectiveness analysis. J Infect Dis 214(5):685–688CrossRef
33.
Laprise J-F, Markowitz LE, Chesson HW, Drolet M, Brisson M (2016) Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis. J Infect Dis 214(5):685–688CrossRef
34.
35.
Smith P, Stokley S, Bednarczyk R, Orenstein W, Omer S (2016) HPV vaccination coverage of teen girls: the influence of health care providers. Vaccine 18(34):1604–1610CrossRef
36.
Rahman M, Laz T, McGrath C, Berenson A (2016) Provider recommendation mediates the relationship between parental human papillomavirus (HPV) vaccine awareness and HPV vaccine initiation and completion among 13- to 17-year-old U.S. adolescent children. Clin Pediatr 54(4):371–375CrossRef
37.
Allison MA, Hurley LP, Marokwitz L, Crane LA, Brtnikova M, Beaty BL, Snow M, Cory J, Stokley S, Roark J, Kempe A (2016) Primary care physicians’ perspectives about HPV vaccine. Pediatrics 137(2):e20152488CrossRef
38.
Kulczycki A, Qu H, Shewchuk R (2016) Primary care physicians’ adherence to guidelines and their likelihood to prescribe the human papillomavirus vaccine for 11- and 12-year-old girls. Women’s Health Issues 26(1):34–39CrossRef
39.
Kyong-No N, Chang K, Cho S, Park S, Park S (2017) Attitudes regarding HPV vaccinations of children among mothers with adolescent daughters in Korea. J Korean Med Sci 32(1):130–134CrossRef
40.
Vermandere H, Naanyu V, Mabeya H, Broeck D, Michielsen K, Degomme O (2014) Determinants of acceptance and subsequent uptake of the HPV vaccine in a cohort in Eldoret, Kenya. PLoS ONE 10(3):e0117761
41.
Cunningham M, Skrastins E, Fitzpatrick R, Jindal P, Olola O, Yeates K, Booth C, Carpenter J, Aronson K (2015) Cervical cancer screening and HPV vaccine acceptability among rural and urban women in Kilimanjaro Region, Tanzania. BMJ Open 5(3):e005828CrossRef
42.
Jaspers L, Budiningsih S, Wolterbeek R, Henderson F, Peters A (2011) Parental acceptance of human papillomavirus (HPV) vaccination in Indonesia: a cross-sectional study. Vaccine 29(44):7785–7793CrossRef
43.
Cover J, Nghi N, LaMontagne D, Huyen D, Hien N, Nga le T (2012) Acceptance patterns and decision-making for human papillomavirus vaccination among parents in Vietnam: an in-depth qualitative study post-vaccination. BMC Public Health 12(629):629CrossRef
44.
Larson H, Jarrett C, Eckersberger E, Smith D, Paterson P (2014) Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007–2012. Vaccine 32(19):2150–2159CrossRef
45.
46.
Ferrer H, Trotter C, Hickman M, Audrey S (2014) Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis. BMC Public Health 14:700CrossRef
47.
Galagan S, Paul P, Menezes L, LaMontagne D (2013) Influences on parental acceptance of HPV vaccination in demonstration projects in Uganda and Vietnam. Vaccine 31(30):3072–3078CrossRef
48.
Widman C, Rodriguez E, Saad-Harfouche F, Tawrozek A, Erwin D, Mahoney M (2017) Clinician and parent perspectives on educational needs for increasing adolescent HPV vaccination. J Cancer Educ 33:332–339CrossRef
Metadata
Title
Acceptability of two- versus three-dose human papillomavirus vaccination schedule among providers and mothers of adolescent girls: a mixed-methods study in five countries
Authors
Jessica Yasmine Islam
Alexis M. Hoyt
Silvina Ramos
Karen Morgan
Chan Joo Kim
Sylvia de Sanjose
Nicole Butera
Virginia Senkomago
Karin L. Richter
Mary Anne McDonald
Nadja A. Vielot
Jennifer S. Smith
Publication date
01-11-2018
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 11/2018
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-018-1085-1

Other articles of this Issue 11/2018

Cancer Causes & Control 11/2018 Go to the issue

Brief report

The association of metformin use with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study

Original paper

Low T-cell subsets prior to development of virus-associated cancer in HIV-seronegative men who have sex with men

Original paper

Occupational variation in the risk of female breast cancer in the Nordic countries

Commentary

Nutritional epidemiology and cancer: A Tale of Two Cities

Original paper

Risk of colon cancer recurrence in relation to diabetes

Original paper

Colorectal cancer incidence among Hispanics and non-Hispanic Whites in the United States
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits